Tags

Type your tag names separated by a space and hit enter

Serum fibroblast growth factor 21 in human obesity: regulation by insulin infusion and relationship with glucose and lipid oxidation.
Int J Obes (Lond) 2013; 37(10):1386-90IJ

Abstract

OBJECTIVE

Fibroblast growth factor 21 (FGF21) reduces plasma glucose and triglycerides, and increases free fatty acid oxidation in animal models of diabetes. The aim of the present study was to assess the relationships of serum FGF21 with glucose oxidation (GOx) and lipid oxidation (LOx) in the baseline and insulin-stimulated conditions in lean and obese subjects.

DESIGN

Cross-sectional study.

SUBJECTS

Eighty-four subjects with normal glucose tolerance, 42 lean (body mass index (BMI) <25 kg m(-2)) and 42 overweight or obese (BMI between 25 and 40 kg m(-2)).

MEASUREMENTS

Euglycemic hyperinsulinemic clamp and indirect calorimetry in the baseline state and during last 30 min of the clamp. The change in respiratory quotient (ΔRQ) in response to insulin was used as a measure of metabolic flexibility. Serum FGF21 was determined in the baseline state and after the clamp.

RESULTS

Obese subjects had higher LOx in the baseline and insulin-stimulated conditions, lower insulin-stimulated GOx and ΔRQ (all P<0.05). Fasting serum FGF21 did not differ between the groups. Insulin infusion resulted in an increase in serum FGF21 in the obese (P=0.0001), but not in the lean group (P=0.76). Postclamp serum FGF21 was higher in the obese subjects (P=0.0007). In this group, postclamp FGF21 was related to LOx during the clamp (r=0.32, P=0.044), change in GOx and LOx in response to insulin (r=-0.44, P=0.005; r=0.47, P=0.002; respectively) and ΔRQ (r=-0.50, P=0.001).

CONCLUSIONS

An increase in serum FGF21 in response to insulin in obese subjects might represent inappropriate response, possibly associated with metabolic inflexibility in obesity and insulin resistance.

Authors+Show Affiliations

1] Department of Endocrinology, Diabetology and Internal Medicine, Medical University of Białystok, Białystok, Poland [2] Department of Prophylaxis of Metabolic Diseases, Institute of Animal Reproduction and Food Research, Polish Academy of Sciences, Olsztyn, Poland.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23419601

Citation

Strączkowski, M, et al. "Serum Fibroblast Growth Factor 21 in Human Obesity: Regulation By Insulin Infusion and Relationship With Glucose and Lipid Oxidation." International Journal of Obesity (2005), vol. 37, no. 10, 2013, pp. 1386-90.
Strączkowski M, Karczewska-Kupczewska M, Adamska A, et al. Serum fibroblast growth factor 21 in human obesity: regulation by insulin infusion and relationship with glucose and lipid oxidation. Int J Obes (Lond). 2013;37(10):1386-90.
Strączkowski, M., Karczewska-Kupczewska, M., Adamska, A., Otziomek, E., Kowalska, I., & Nikołajuk, A. (2013). Serum fibroblast growth factor 21 in human obesity: regulation by insulin infusion and relationship with glucose and lipid oxidation. International Journal of Obesity (2005), 37(10), pp. 1386-90. doi:10.1038/ijo.2013.10.
Strączkowski M, et al. Serum Fibroblast Growth Factor 21 in Human Obesity: Regulation By Insulin Infusion and Relationship With Glucose and Lipid Oxidation. Int J Obes (Lond). 2013;37(10):1386-90. PubMed PMID: 23419601.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Serum fibroblast growth factor 21 in human obesity: regulation by insulin infusion and relationship with glucose and lipid oxidation. AU - Strączkowski,M, AU - Karczewska-Kupczewska,M, AU - Adamska,A, AU - Otziomek,E, AU - Kowalska,I, AU - Nikołajuk,A, Y1 - 2013/02/19/ PY - 2012/07/27/received PY - 2012/12/07/revised PY - 2013/01/09/accepted PY - 2013/2/20/entrez PY - 2013/2/20/pubmed PY - 2014/6/11/medline SP - 1386 EP - 90 JF - International journal of obesity (2005) JO - Int J Obes (Lond) VL - 37 IS - 10 N2 - OBJECTIVE: Fibroblast growth factor 21 (FGF21) reduces plasma glucose and triglycerides, and increases free fatty acid oxidation in animal models of diabetes. The aim of the present study was to assess the relationships of serum FGF21 with glucose oxidation (GOx) and lipid oxidation (LOx) in the baseline and insulin-stimulated conditions in lean and obese subjects. DESIGN: Cross-sectional study. SUBJECTS: Eighty-four subjects with normal glucose tolerance, 42 lean (body mass index (BMI) <25 kg m(-2)) and 42 overweight or obese (BMI between 25 and 40 kg m(-2)). MEASUREMENTS: Euglycemic hyperinsulinemic clamp and indirect calorimetry in the baseline state and during last 30 min of the clamp. The change in respiratory quotient (ΔRQ) in response to insulin was used as a measure of metabolic flexibility. Serum FGF21 was determined in the baseline state and after the clamp. RESULTS: Obese subjects had higher LOx in the baseline and insulin-stimulated conditions, lower insulin-stimulated GOx and ΔRQ (all P<0.05). Fasting serum FGF21 did not differ between the groups. Insulin infusion resulted in an increase in serum FGF21 in the obese (P=0.0001), but not in the lean group (P=0.76). Postclamp serum FGF21 was higher in the obese subjects (P=0.0007). In this group, postclamp FGF21 was related to LOx during the clamp (r=0.32, P=0.044), change in GOx and LOx in response to insulin (r=-0.44, P=0.005; r=0.47, P=0.002; respectively) and ΔRQ (r=-0.50, P=0.001). CONCLUSIONS: An increase in serum FGF21 in response to insulin in obese subjects might represent inappropriate response, possibly associated with metabolic inflexibility in obesity and insulin resistance. SN - 1476-5497 UR - https://www.unboundmedicine.com/medline/citation/23419601/Serum_fibroblast_growth_factor_21_in_human_obesity:_regulation_by_insulin_infusion_and_relationship_with_glucose_and_lipid_oxidation_ L2 - http://dx.doi.org/10.1038/ijo.2013.10 DB - PRIME DP - Unbound Medicine ER -